Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: A meta-analysis

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 9, 2008, Pages 994-1002

  Sun, F ^a   Chen, Y ^b   Xiang, Y ^c   Zhan, S ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Anti tuberculosis drug induced liver injury; Arylamine N acetyltransferase; Cytochrome P450 2E1; Drug metabolising enzymes; Glutathione S transferase; Meta analysis

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2E1; DRUG METABOLIZING ENZYME; TUBERCULOSTATIC AGENT;

CBMDISC; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA EXTRACTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; EMBASE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER INJURY; LIVER TOXICITY; MEDLINE; META ANALYSIS; NULL ALLELE; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TUBERCULOSTATIC DRUG INDUCED LIVER INJURY; WILD TYPE;

ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2E1; DISEASE SUSCEPTIBILITY; GENOTYPE; GLUTATHIONE TRANSFERASE; HEPATITIS, TOXIC; HUMANS; POLYMORPHISM, GENETIC; RISK; TUBERCULOSIS, PULMONARY;

EID: 51149118041     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Huang Y S, Su W J, Huang YH, et al. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to anti-tuberculosis drug-induced liver injury. Expert Opinion on Drug Metabolism Toxicol 2007; 3: 1-8.
2. Frieden T R, Sterling T R, Munsiff S S, Watt C J, Dye C. Tuberculosis. Lancet 2003; 362: 887-899.
3. Hussain Z, Kar P, Husain S A. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Ind J Exp Biol 2003; 41: 1226-1232.
4. Agal S, Baijal R, Pramanik S, et al. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 2005; 20: 1745-1752.
5. Yew W W, Leung C C. Anti-tuberculosis drugs and hepatotoxicity. Respirology 2006; 11: 699-707.
6. Fountain F F'Tolley E, Chrisman C R, Self T H. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128: 116-123.
7. Zhang P. Anti-tubercular agent injuries to the liver in liver disease. Chinese J Tuberc Respir Dis 1998; 21: 643-644.
8. Hwang S J, Wu J C, Lee C N, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for Hepatitis B. J Gastroenterol Hepatol 1997; 12: 87-91.
9. Parthasarathy R, Sarma G R, Janardhanam B, et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986; 67: 99-108.
10. Askgaard D S, Wilcke T, Dossing M. Hepatotoxicity caused by the combined action of isoniazid and rifampicin. Thorax 1995; 50: 213-214.
11. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Safety 1996; 15: 394-405.
12. Dowda M, Sy F S, Dowda H, Pozsik C J. Correlates of hepatotoxicity and anti-tuberculosis therapy in South Carolina. J S C Med Assoc 1998; 94: 16-20.
13. Salpeter S R. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993; 159: 560-564.
14. Steele M A, Burk R F, DesPrez R M. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-471.
15. Xue H Y, Hou Y N, Liu H C. The general investigation of the increased hepatotoxicity caused by isoniazid in combination with rifampin. Chinese J Mod Applied Pharm 2002; 19: 463-465.
16. Tostmann A, Boeree M J, Aarnoutse R E, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2007; 6: 1440-1446.
17. Farrell G C. Drug-induced acute hepatitis. In: Drug-induced liver disease. Farrell G C, ed. Edinburgh, UK: Churchill Livingstone, 1994: pp 262-272.
18. Mitchell J R, Zimmerman H J, Ishak G, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976; 84: 181-192.
19. Runge-Morris M, Feng Y, Zangar R C, Novak R F. Effects of hydrazine, phenelzine, and hydralazine treatmenton rat hepatic and renal drug-metabolizing enzyme expression. Drug Metab Dispos 1996; 24: 734.
20. Sarma G R, Immanuel C, Kailasam S, Narayana A S, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986; 133: 1072-1075.
21. Strange R C, Jones P W, Fryer A A. Glutathione S-transferase: genetics and role in toxicology. Toxicol Lett 2000; 112-113: 357-363.
22. Hughes H B, Biehl J P, Jones A P, Schmidt L H. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 1954; 70: 266-273.
23. Dickinson D S, Bailey W C, Hirschowitz B I, et al. Risk factors for isoniazid (NIH)-induced liver dysfunction. J Clin Gastroenterol 1981; 3: 271-279.
24. Pande J N, Singh S P N, Khilnani G C, Khilnani S, Tandon R K. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-136.
25. Dan H L, Bai Y, Zhang Y L, Nie J. Meta-analysis method and its research value and appraisal in medicine science Chinese. J Med Sci Res Manage 2003; 16: 12-15.
26. Petitti D B. Meta-analysis, decision analysis and cost-effectiveness. New York, NY, USA: Oxford University Press, 1994.
27. Little J, Bradley L, Bray M S, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002; 156: 300-310.
28. Lau J, Ioannidis J P, Schmid C H. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-826.
29. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
30. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
31. Normand S L. Meta-analysis: formulating, evaluating, combining and reporting. Stat Med 1999; 18: 321-359.
32. John C, Jian Q S. Meta-analysis, funnel plots and sensitivity analysis. Biostat 2000; 1: 247-262.
33. Orwin R G. A fail-safe N for effect size in meta-analysis. J Edu Stat 1983; 8: 157-159.
34. Huang Y S, Su W J, Huang Y H, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P) H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007; 47: 128-134.
35. Wang J H, Liu J W, Wu X Q, et al. The study on the susceptible gene of isoniazid and rifampicin-induced hepatotoxicity of pulmonary tuberculosis patients. Acad J Pla Postgraduate Med School 2004; 25: 239-240.
36. Wang T, Wang W. Relationship between cytochrome P450-2E1 polymorphisms and the susceptibility to anti-tuberculosis drug-induced hepatitis. Master's thesis. Beijing Postgraduate Medical School of China: PLA China, 2006.
37. Roy B, Chowdhury A, Kundu S, et al. Increased risk of anti-tuberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001; 16: 1033-1037.
38. Huang Y S, Chern H D, Su W J, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for anti-tuberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.
39. Huang Y S, Chern H D, Su W J, et al. Cytochrome P450 2E1 genotype and the susceptibility to anti-tuberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.
40. Roy B, Ghosh S K, Sutradhar D, et al. Predisposition of anti-tuberculosis drug induced hepatotoxicity by cytochrome P4502E1 genotype and haplotype in pediatric patients. J Gastroenterol Hepatol 2006; 21: 784-786.
41. Shimizu Y, Dobashi K, Mita Y, et al. DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity. Tuberculosis 2006; 86: 374-381.
42. Vuilleumier N, Rossier M F, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62: 423-429.
43. Kita T, Tanigawara Y, Chikazawa S, et al. N-acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol Pharmaceutical Bull 2001; 24: 544-549.
44. Chen B, Li J H, Xu Y M, Wang J, Cao X M. The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients. Clin Chim Acta 2006; 365: 104-108.
45. Zimmerman H J. Hepatic injury from the treatment of infectious and parasitic diseases. In: Zimmerman H J, ed. Hepatotoxicity. Philadelphia, PA, USA: Lippincott Williams & Wilkins 1999: pp 589-637.
46. Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000; 4: 256-261.
47. Dye C, Scheele S, Dolin P, Pathania V, Raviglione M. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-686.
48. Wong W M, Wu P C, Yuen M F, et al. Anti-tuberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31: 201-206.
49. Lee S Y, Lee K A, Ki C S, et al. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. Clin Chem 2002; 48: 775-777.
50. Meyer D J, Coles B, Pemble S E, et al. Theta: a new class of glutathione transferases purified from rat and man. Biochem J 1991; 274: 409-414.
51. Mitchell J R, Thorgeirsson U P, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clin Pharmacol Ther 1975; 18: 70-72.